The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Alexion Pharmaceuticals Partners with the Connecticut Community Foundation to Award Scholarships to Eight Waterbury, Connecticut Public High School Graduates

<p class='bwalignc'> <b>Scholars Excel in Life Sciences and Chemistry</b> </p>

Tuesday, July 26, 2011

Alexion Pharmaceuticals Partners with the Connecticut Community Foundation to Award Scholarships to Eight Waterbury, Connecticut Public High School Graduates09:00 EDT Tuesday, July 26, 2011 WATERBURY, Conn. (Business Wire) -- Eight graduating seniors with an interest in the life sciences or chemistry from four different Waterbury, Connecticut Public High Schools have each been awarded a 2011 Alexion Scholarship. The 2011 Alexion Scholars were selected by their high school principals, based on factors that include their academic achievement and career plans. Each 2011 Alexion Scholar will receive $4,000, paid over the four years of his/her undergraduate studies. In total, the Alexion Scholarship Fund, at the Connecticut Community Foundation, is now supporting the educational goals of 16 Alexion Scholars. “As a company that develops life-transforming therapies for patients with ultra-rare, life-threatening diseases, Alexion is pleased to support students who are interested in careers related to the sciences and healthcare,” said Dan Caron, Vice President, Site Operations and Engineering at Alexion. “We look forward to helping these promising students complete their educations by contributing to their expenses in each year of their college studies.” About Alexion Alexion Pharmaceuticals, Inc., based in Cheshire Connecticut, is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition, and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH, a debilitating, ultra-rare and life-threatening blood disorder. Soliris is approved in more than 35 countries. Alexion is evaluating other potential indications for Soliris and is pursuing development of other innovative biotechnology product candidates in early stages of development. About the Connecticut Community Foundation Founded in 1923 as the Waterbury Foundation, the Connecticut Community Foundation was the first community foundation in the state. The Foundation connects you to the causes you care about. Serving 21 towns in Greater Waterbury and the Litchfield Hills, the Foundation administers more than 380 charitable funds established by local donors. Funds reflect a variety of philanthropic interests and support a range of giving opportunities in the arts, environment, health care, education, human services and women's and children's initiatives. With this support, the Foundation provides grants and services to nonprofit organizations and scholarships to students. Volunteers and staff offer their expertise by serving on committees and supporting special initiatives that effect positive change, growth and improve the quality of life in our region. For more information, go to www.conncf.org. [ALXN-G] Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6805656&lang=en Alexion Corporate Communications and Public PolicyIrving Adler, 203-271-8210Senior DirectororConnecticut Community FoundationKristine Mascoli, 203-753-1315